KR920700288A - 펲티드 및 dna배열 - Google Patents

펲티드 및 dna배열

Info

Publication number
KR920700288A
KR920700288A KR1019900700595A KR900700595A KR920700288A KR 920700288 A KR920700288 A KR 920700288A KR 1019900700595 A KR1019900700595 A KR 1019900700595A KR 900700595 A KR900700595 A KR 900700595A KR 920700288 A KR920700288 A KR 920700288A
Authority
KR
South Korea
Prior art keywords
leu
ser
phe
acid sequence
polypeptide
Prior art date
Application number
KR1019900700595A
Other languages
English (en)
Other versions
KR100195632B1 (ko
Inventor
로버트 굳데이 앤드류우
폴 벨필드 그라함
슬립 다렐
Original Assignee
알란 에스 톰슨
델타 바이오테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888817598A external-priority patent/GB8817598D0/en
Priority claimed from GB898906920A external-priority patent/GB8906920D0/en
Application filed by 알란 에스 톰슨, 델타 바이오테크놀로지 리미티드 filed Critical 알란 에스 톰슨
Publication of KR920700288A publication Critical patent/KR920700288A/ko
Application granted granted Critical
Publication of KR100195632B1 publication Critical patent/KR100195632B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)

Abstract

내용 없음

Description

펩티드 및 DNA배열
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 폴리스미드 pEK113의 제한효소지도이다,
제2도는 폴리스미드 pEK25의 제한효소지도이다,
제3도는 폴리스미드 pAYE230의 제한효소지도이다.

Claims (12)

  1. 하기와 같은 아미노산 배열:
    (a)H N－Met－Lys－Trp－Val－Ser－Phe－lle－Ser－Leu－Leu－Phe－Leu－Phe－Ser－Ser－Ala－Tyr－Ser－Arg－Ser－Leu－Asp－Lys－Arg－COOH 또는 (b)H N－Met－Asn－lle－Phe－tyr－lle－Phe－Leu－Phe－Leu－Leu－Ser－Phe－Val－Gln－Gly－Ser－Leu－Asp－Lys－Arg－COOH 또는 상기 어느 배열의 보전적 수식 변이형.
  2. 카르복실 말단에서 폴리펩티드의 N－말단 잔기에 연결된 제1항의 아미노산 배열을 포함하고 있는 융합체.
  3. 제2항에 있어서, 상기 아미노산 배열이 상기 폴립펩티드에 직접 연결되어 있는 융합체.
  4. 제3항에 있어서, 폴리펩티드가 자연발생 인체혈청 알부민, 수식된 인체형청 알부민 또는 상기 둘중 어느 것의 단편인 융합체.
  5. 제1항의 아미노산 배열 또는 제2항의 융합체에 대한 암호화 핵산배열.
  6. 제5항에 있어서, 표2 또는 표3에 제시된 배열로부터 선택된 핵산배열.
  7. 적절한 조절영역 또는 영역들 및, 조절영역의 조절하에 있는 제5항 또는 제6항의 핵산배열을 포함하는 DNA 구조.
  8. 제7항의 DNA구조로 형질전환된 숙주.
  9. 제8항의 사카로미세스 세레비지에(Saccharomyces cerevisiae) 또는 시조사카로미세스 폼베(Schizosaccharomyces pombe).
  10. 제8항 또는 제9항의 숙주를 배양하고 그들로부터 상기 핵산배열 또는 그 수식 변역체에 의하여 발현된 폴리펩티드를 얻는 것을 포함하는 폴리펩티드의 제조방법.
  11. 제10항의 방법으로 제조된 폴리펩티드.
  12. 제10항의 방법으로 제조된 인체혈청 알부빈 또는 그 변이형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019900700595A 1988-07-23 1989-07-14 펩티드 및 dna 배열 KR100195632B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB888817598A GB8817598D0 (en) 1988-07-23 1988-07-23 Dna & peptide sequences
GB8817598.9 1988-07-23
GB898906920A GB8906920D0 (en) 1989-03-28 1989-03-28 Peptide and dna sequences
GB8906920.7 1989-03-28
GB896920.7 1989-03-28
PCT/GB1989/000816 WO1990001063A1 (en) 1988-07-23 1989-07-14 New secretory leader sequences
GBPGB89/00816 1989-07-14

Publications (2)

Publication Number Publication Date
KR920700288A true KR920700288A (ko) 1992-02-19
KR100195632B1 KR100195632B1 (ko) 1999-06-15

Family

ID=26294196

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700595A KR100195632B1 (ko) 1988-07-23 1989-07-14 펩티드 및 dna 배열

Country Status (15)

Country Link
US (1) US5302697A (ko)
EP (1) EP0387319B1 (ko)
JP (1) JP3092811B2 (ko)
KR (1) KR100195632B1 (ko)
AT (1) ATE135045T1 (ko)
AU (1) AU633020B2 (ko)
CA (1) CA1340547C (ko)
DE (1) DE68925893T2 (ko)
DK (1) DK175853B1 (ko)
FI (1) FI104564B (ko)
GB (1) GB2230268B (ko)
HU (1) HU213571B (ko)
IE (1) IE62266B1 (ko)
IL (1) IL91024A (ko)
WO (1) WO1990001063A1 (ko)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5759802A (en) * 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE69636536T2 (de) * 1995-02-03 2007-10-25 Asahi Glass Co., Ltd. Sekretionssignal-Gen und dieses enthaltender Expressionsvektor
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2475382A1 (en) 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
GB0217033D0 (en) * 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
MXPA06006392A (es) 2003-12-05 2007-03-15 Childrens Hosp Medical Center Composiciones de oligosacaridos y uso de estas en el tratamiento de infecciones.
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
JP5631533B2 (ja) 2004-12-23 2014-11-26 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ 遺伝子発現技術
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
US7803769B2 (en) * 2006-10-25 2010-09-28 Amgen Inc. OSK1 peptide analogs and pharmaceutical compositions
AU2008262490B2 (en) * 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2594583A1 (en) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
DK2393834T3 (da) 2009-02-06 2013-06-24 Novozymes Biopharma Dk As Fremgangsmåde til oprensning
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
JP2013535692A (ja) 2010-08-10 2013-09-12 アムジエン・インコーポレーテツド 標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
KR20130110169A (ko) 2010-09-22 2013-10-08 암젠 인크 담체 면역글로뷸린 및 이것의 용도
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
EA201391331A1 (ru) 2011-03-16 2014-02-28 Эмджен Инк. Активные и селективные ингибиторы nav1.3 и nav1.7
CA2864702A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US11078464B2 (en) 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
WO2016061141A1 (en) 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
CA2964313C (en) 2014-10-15 2023-03-14 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN108431204A (zh) 2015-12-22 2018-08-21 阿尔布梅迪克斯医疗有限公司 改良的表达蛋白质的菌株
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
AU2018286919B2 (en) 2017-06-20 2022-10-06 Albumedix Ltd. Improved protein expression strains
KR102578087B1 (ko) 2017-08-17 2023-09-18 저스트-에보텍 바이오로직스, 아이엔씨. 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
US20210170029A1 (en) 2017-11-20 2021-06-10 Just-Evotec Biologies, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
US20220119757A1 (en) 2019-02-15 2022-04-21 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4370647A1 (en) 2021-07-15 2024-05-22 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
WO2023154305A2 (en) 2022-02-10 2023-08-17 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207925A (en) * 1983-04-25 1988-05-30 Genentech Inc Yeast expression vehicle consisting of a yeast promoter and signal peptide encoding region linked to a heterologus peptide coding region; expression and culture
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
RU2091490C1 (ru) * 1985-10-25 1997-09-27 Зимодженетикс, Инк. Способ получения гетерологичного полипептида в эукариотических микроорганизмов
HU206897B (en) * 1985-10-25 1993-01-28 Zymogenetics Inc Process for utilizing bar-1 gen for selecting strange proteins
GB8613388D0 (en) * 1986-06-03 1986-07-09 Delta Biotechnology Ltd Induction of galactose regulated gene expression in yeast
IT1196484B (it) * 1986-07-11 1988-11-16 Sclavo Spa Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
JP2507874B2 (ja) * 1986-11-27 1996-06-19 工業技術院長 分泌シグナルペプチドをコ−ドするｄｎａ配列

Also Published As

Publication number Publication date
AU633020B2 (en) 1993-01-21
DE68925893D1 (de) 1996-04-11
JP3092811B2 (ja) 2000-09-25
CA1340547C (en) 1999-05-18
KR100195632B1 (ko) 1999-06-15
GB8928849D0 (en) 1990-07-18
US5302697A (en) 1994-04-12
EP0387319B1 (en) 1996-03-06
ATE135045T1 (de) 1996-03-15
IE62266B1 (en) 1995-01-11
GB2230268B (en) 1992-01-29
EP0387319A1 (en) 1990-09-19
IL91024A (en) 1995-08-31
HU213571B (en) 1997-08-28
FI901428A0 (fi) 1990-03-21
FI104564B (fi) 2000-02-29
HU894572D0 (en) 1991-05-28
GB2230268A (en) 1990-10-17
DK175853B1 (da) 2005-04-04
HUT57829A (en) 1991-12-30
AU4042789A (en) 1990-02-19
DE68925893T2 (de) 1996-08-08
IE892361L (en) 1990-01-23
DK72990D0 (da) 1990-03-21
WO1990001063A1 (en) 1990-02-08
JPH03500370A (ja) 1991-01-31
DK72990A (da) 1990-03-21
IL91024A0 (en) 1990-02-09

Similar Documents

Publication Publication Date Title
KR920700288A (ko) 펲티드 및 dna배열
KR987000085A (ko) 헤지호그-유래의 신규한 폴리펩티드(Novel Hedgehog-Derived Polypeptides)
DK105489D0 (da) Polypeptid
JP3730256B2 (ja) 分泌シグナル遺伝子およびそれを有する発現ベクター
EP0509553A1 (en) Anti-lymphotoxin antibody, its production and use
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
ATE68014T1 (de) Die synthese eines proteins mittels eines identifizierungspeptids.
KR890010199A (ko) 활성화된 사람의 단백질 c의 직접 발현용 벡터 및 화합물
ATE63757T1 (de) Expression durch verwendung von fusionsgenen fuer proteinproduktion.
KR890010198A (ko) 효모에서 외래단백질을 제조하는 방법, 재조합 dna 및 형질전환체
DE69030937D1 (de) Mutanten von Interleukin-3
ATE317443T1 (de) N-terminal verlängerte proteine exprimiert in hefe
WO1997012044A3 (en) Pichia secretory leader for protein expression
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
EP0750040A3 (en) Macrophage stimulating protein variant and method for producing the same
JPS6443193A (en) Production of phospholipase a2
RU92004585A (ru) Промотор, днк-последовательность, вектор, клетки, способ экспрессии днк
Karkhanis et al. Antigenic subunit of the polypeptide antigenic complex of the Melvin strain of Neisseria gonorrhoeae
KR910700341A (ko) 합성 인터루킨-6

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120203

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee